# CERO THERAPEUTICS HLDGS INC (CERO)

> Institutional ownership reported to the SEC as of Q3 2025, from Form 13F filings. Source: https://holderbook.com/stocks/CERO/

- Reporting holders: 10
- Reported value: $798.7K
- Shares held by institutions: 156,980 of 1,205,402 outstanding
- Held through calls: 0.0%
- Held through puts: 0.0%

A 13F reports long US equity positions only. Shorts, bonds, foreign listings and cash are not visible here, and positions are disclosed up to 45 days after the quarter ends.

## Largest holders

| Manager | Value | Shares | Share of their book | Quarters held |
|---|---|---|---|---|
| [Parallel Advisors, LLC](https://holderbook.com/funds/1690010-parallel-advisors-llc/) | $615.9K | 121,000 | 0.0% | 2 |
| [ARCH Venture Management, LLC](https://holderbook.com/funds/1274403-arch-venture-management-llc/) | $114.0K | 22,389 | 0.0% | 2 |
| [SUSQUEHANNA INTERNATIONAL GROUP, LLP](https://holderbook.com/funds/1446194-susquehanna-international-group-llp/) | $52.1K | 10,244 | 0.0% | 1 |
| [Tower Research Capital LLC (TRC)](https://holderbook.com/funds/1533421-tower-research-capital-llc-trc/) | $6.6K | 1,299 | 0.0% | 2 |
| [FNY Investment Advisers, LLC](https://holderbook.com/funds/1742998-fny-investment-advisers-llc/) | $5.0K | 1,050 | 0.0% | 2 |
| [CITIGROUP INC](https://holderbook.com/funds/831001-citigroup-inc/) | $4.9K | 968 | 0.0% | 1 |
| [SBI Securities Co., Ltd.](https://holderbook.com/funds/1851815-sbi-securities-co-ltd/) | $92 | 18 | 0.0% | 2 |
| [UBS Group AG](https://holderbook.com/funds/1610520-ubs-group-ag/) | $30 | 6 | 0.0% | 2 |
| [JONES FINANCIAL COMPANIES LLLP](https://holderbook.com/funds/815917-jones-financial-companies-lllp/) | $16 | 3 | 0.0% | 2 |
| [BANK OF AMERICA CORP /DE/](https://holderbook.com/funds/70858-bank-of-america-corp-de/) | $15 | 3 | 0.0% | 2 |

## Quarter by quarter

| Quarter | Holders | Reported value |
|---|---|---|
| Q3 2025 | 10 | $798.7K |
| Q2 2025 | 8 | $2.4M |
| Q1 2025 | 14 | $527.7K |
| Q4 2024 | 20 | $801.0K |
| Q3 2024 | 17 | $321.2K |
| Q2 2024 | 14 | $561.0K |
| Q1 2024 | 9 | $4.9M |
| Q4 2023 | 9 | $10.2M |
| Q3 2023 | 9 | $7.3M |
| Q2 2023 | 13 | $11.8M |
| Q1 2023 | 15 | $12.5M |
| Q4 2022 | 45 | $101.1M |